Capillary Biomedical, Inc. (CapBio) is a medical device startup developing technologies for diabetes management. We aim to dramatically simplify insulin delivery, reducing the burden on both patients and the overall healthcare system. CapBio's first product is the patent-pending SteadiSet infusion set for insulin pump therapy. It's SteadiFlow technology features a kink-proof, super-soft cannula with multi-port delivery designed for reliable and comfortable insulin delivery. Our user-friendly insertion device makes it easy. The company is based in Irvine, CA and is a spin-out of the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA. This ongoing academic-industry collaboration is focused on improving the comfort, reliability and predictability of insulin infusion therapy. Together, we aim to achieve more consistent and reliable insulin absorption, which will enable people with diabetes to achieve improved blood glucose control.
Looking for a particular Capillary Biomedical employee's phone or email?
The Capillary Biomedical annual revenue was $800000 in 2026.
Jeffrey Joseph is the Director of Market Research of Capillary Biomedical.
8 people are employed at Capillary Biomedical.
Capillary Biomedical is based in Irvine, California.
The NAICS codes for Capillary Biomedical are [339, 33].
The SIC codes for Capillary Biomedical are [384, 38].